Soleno Therapeutics (SLNO) EBT Margin (2015 - 2026)

Soleno Therapeutics (SLNO) posted quarterly EBT Margin of 36.9% for Q1 2026, down 21.92% quarter-over-quarter from 47.27% in Q4 2025.

Soleno Therapeutics (SLNO) EBT Margin (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has reported EBT Margin for 5 consecutive years, with 36.9% the latest figure, recorded in Q1 2026.

In Q1 2026, EBT Margin changed N/A year-over-year to 36.9%; the TTM figure through Mar 2026 stood at 63.79% (changed N/A YoY), while the FY2025 annual figure was 28.12%, changed N/A from the prior year.
EBT Margin retreated to 36.9% in Q1 2026 per SLNO's latest filing, from 47.27% in the prior quarter.
Across five years, EBT Margin topped out at 47.27% in Q4 2025 and bottomed at 532.56% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Soleno Therapeutics	2.74 Bn	2.49 Bn	93.41 Mn	36.90%

Download Data